(Q36576959)

15 August 2017

1 reference

title

Drug insight: Small-molecule inhibitors of protein kinases in the treatment of thyroid cancer (English)

1 reference

15 August 2017

Massimo Santoro

1

1 reference

15 August 2017

Francesca Carlomagno

series ordinal

2

1 reference

15 August 2017

publication date

1 January 2006

1 reference

Nature Clinical Practice Endocrinology and Metabolism

15 August 2017

published in

1 reference

15 August 2017

volume

2

1 reference

15 August 2017

issue

1

1 reference

15 August 2017

page(s)

42-52

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

15 August 2017

1 reference

7 January 2021

Papillary and follicular thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

How thyroid tumors start and why it matters: kinase mutants as targets for solid cancer pharmacotherapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

BRAF mutation in thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

PTEN: one gene, many syndromes

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The PAX8/PPAR gamma fusion oncogene as a potential therapeutic target in follicular thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Anaplastic thyroid carcinoma: a therapeutic challenge.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Molecular genetics of multiple endocrine neoplasia types 1 and 2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Evolving strategies for targeted cancer therapy--past, present, and future

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Prophylactic thyroidectomy in multiple endocrine neoplasia type 2A.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Targeted cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Issues and progress with protein kinase inhibitors for cancer treatment

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Strategies to overcome resistance to targeted protein kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The GDNF family: signalling, biological functions and therapeutic value

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Minireview: RET: normal and abnormal functions

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

A targeting mutation of tyrosine 1062 in Ret causes a marked decrease of enteric neurons and renal hypoplasia

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The RET/PTC-RAS-BRAF linear signaling cascade mediates the motile and mitogenic phenotype of thyroid cancer cells

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Mutations of theRET proto-oncogene in the multiple endocrine neoplasia type 2 syndromes, related sporadic tumours, and Hirschsprung disease

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Molecular diagnosis of multiple endocrine neoplasia Type 2.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

RET proto-oncogene: a review and update of genotype-phenotype correlations in hereditary medullary thyroid cancer and associated endocrine tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Efficient inhibition of RET/papillary thyroid carcinoma oncogenic kinases by 4-amino-5-(4-chloro-phenyl)-7-(t-butyl)pyrazolo[3,4-d]pyrimidine (PP2).

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Cellular effects and antitumor activity of RET inhibitor RPI-1 on MEN2A-associated medullary thyroid carcinoma

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

ZD6474--a novel inhibitor of VEGFR and EGFR tyrosine kinase activity

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Regulation of p27Kip1 protein levels contributes to mitogenic effects of the RET/PTC kinase in thyroid carcinoma cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

ZD6474 suppresses oncogenic RET isoforms in a Drosophila model for type 2 multiple endocrine neoplasia syndromes and papillary thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Disease associated mutations at valine 804 in the RET receptor tyrosine kinase confer resistance to selective kinase inhibitors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Germline Homozygous Mutations at Codon 804 in theRETProtooncogene in Medullary Thyroid Carcinoma/Multiple Endocrine Neoplasia Type 2A Patients

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Targeting the mitogen-activated protein kinase cascade to treat cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Investigation of BRAF mutation in a series of papillary thyroid carcinoma and matched-lymph node metastasis reveals a new mutation in metastasis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Targeted expression of BRAFV600E in thyroid cells of transgenic mice results in papillary thyroid cancers that undergo dedifferentiation.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

BRAF mutations in thyroid tumors are restricted to papillary carcinomas and anaplastic or poorly differentiated carcinomas arising from papillary carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Oncogenic AKAP9-BRAF fusion is a novel mechanism of MAPK pathway activation in thyroid cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Raf: a strategic target for therapeutic development against cancer

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

17-Allylamino-17-demethoxygeldanamycin activity against thyroid cancer cell lines correlates with heat shock protein 90 levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Effects of PTK787/ZK222584, a Tyrosine Kinase Inhibitor, on the Growth of a Poorly Differentiated Thyroid Carcinoma: An Animal Study

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Antivascular therapy of human follicular thyroid cancer experimental bone metastasis by blockade of epidermal growth factor receptor and vascular growth factor receptor phosphorylation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Drug discovery: playing dirty

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Activation of the hepatocyte growth factor (HGF)-Met system in papillary thyroid cancer: biological effects of HGF in thyroid cancer cells depend on Met expression levels

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Cancer therapy: can the challenge be MET?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Fibroblast growth factor receptors as molecular targets in thyroid carcinoma.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Epidermal growth factor receptor (EGFR) is overexpressed in anaplastic thyroid cancer, and the EGFR inhibitor gefitinib inhibits the growth of anaplastic thyroid cancer.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Efficacy of epidermal growth factor receptor-targeted molecular therapy in anaplastic thyroid cancer cell lines

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The selective tyrosine kinase inhibitor, STI571, inhibits growth of anaplastic thyroid cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Imatinib mesylate (gleevec; STI571) monotherapy is ineffective in suppressing human anaplastic thyroid carcinoma cell growth in vitro

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Akt: a potential target for thyroid cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Uncommon Mutation, but Common Amplifications, of thePIK3CAGene in Thyroid Tumors

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The Akt inhibitor KP372-1 suppresses Akt activity and cell proliferation and induces apoptosis in thyroid cancer cells.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The TOR pathway: a target for cancer therapy

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Expression of the neoplastic phenotype by human thyroid carcinoma cell lines requires NFkappaB p65 protein expression.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Oncogenic and anti-apoptotic activity of NF-kappa B in human thyroid carcinomas

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

The IKK NF-kappa B system: a treasure trove for drug development

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Editorial: anaplastic carcinoma of the thyroid--will aurora B light a path for treatment?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Aurora B overexpression associates with the thyroid carcinoma undifferentiated phenotype and is required for thyroid carcinoma cell proliferation

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Aurora kinases: shining lights on the therapeutic horizon?

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Progress in the discovery of polo-like kinase inhibitors.

1 reference

https://api.crossref.org/works/10.1038%2FNCPENDMET0073

7 January 2021

Identifiers

DOI

10.1038/NCPENDMET0073

1 reference

15 August 2017

1 reference